Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction

Heart

Volumn 75, Issue 1, 1996, Pages 23-28

  Rodriguez, Luz Maria ^a   Sternick, Eduardo B ^a   Smeets, Joep L R M ^a   Timmermans, Carl ^a   Den Dulk, Karel ^a   Oreto, Giuseppe ^a   Wellens, Hein J J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Myocardial infarction; Programmed electrical stimulation; Sudden death; Ventricular arrhythmias

Indexed keywords

AMIODARONE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROPHYSIOLOGY; FEMALE; HEART VENTRICLE FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SUDDEN DEATH;

EID: 0030045318     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.75.1.23     Document Type: Article

References (20)

1. Heger JJ, Prystowsky EN, Jackman WM, Nacarelli GV, Warfel KA, Rinkenberger RL, et al. Amiodarone: clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 1981;305:539-45.
2. Hamer AW, Finerman WB, Peter T, Mandel WJ. Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias. Am Heart J 1981;102:992-1000.
3. Waxman HL, Groh WC, Marchlinski FE, Buxton AE, Sadowski LM, Horowitz LN, et al. Amiodarone for control of sustained ventricular tachyarrhythmias. Clinical and electrophysiologic effects in 51 patients. Am J Cardiol 1982;50:1066-74.
4. Nademanee K, Hendrickson JA, Jannan R, Singh BH. Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia. Am Heart J 1982;103: 950-9.
5. Horowitz LN, Greenspan AM, Spielman SR, Webb CR, Morganroth J, Rotmensch H, et al. Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary artery disease. Am J Cardiol 1985;55: 367-71.
6. McGovern B, Garan H, Malacoff RF, DiMarco JP, Garant G, Sellers D, et al. Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. Am J Cardiol 1984;53:1558-63.
7. Nacarelli GV, Fineberg NS, Zipes DP, Heger JJ, Duncan G, Prystowsky EN. Amiodarone: risk factors for recurrences of symptomatic ventricular tachycardia identified at electrophysiologic study. J Am Coll Cardiol 1985;68: 814-21.
8. Klein LS, Fineberg N, Heger JJ, Miles WM, Kammerling JM, Chang M-S, et al. Prospective evaluation of a descriminant function for prediction of recurrent ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrophysiologic study. Am J Cardiol 1988;61:1024-30.
9. Kadish AH, Buxton AE, Waxman HL, Flores B, Josephson ME, Marchlinski FE. Usefulness of electrophysiologic study to determine the clinical tolerance of arrhythmia recurrences during amiodarone therapy. J Am Coll Cardiol 1987;10:90-6.
10. Zhu J, Haines DE, Lerman BB, DiMarco JP. Predictors of efficacy of amiodarone and characteristics of recurrence of arrhythmia in patients with sustained ventricular tachycardia and coronary artery disease. Circulation 1987; 76:802-9.
11. Manolis AS, Urichio F, Estes ME. Prognostic value of early electrophysiologic studies for ventricular tachycardia recurrence in patients with coronary artery disease treated with amiodarone. Am J Cardiol 1989;63:1052-7.
12. Kim SG, Felder SD, Figura I, Johnston DR, Mercado AD, Fisher JD. Prognostic value of changes in the mode of ventricular tachycardia induction during therapy with amiodarone and class 1A antiarrhythmic agent. Am J Cardiol 1987;59:1314-8.
13. Brugada P, Wellens HJJ. Programmed electrical stimulation of the human heart. In: Josephson ME, Wellens HJJ, eds. Tachycardias; mechanism, diagnosis and treatment. Philadelphia: Lea and Febiger, 1984;61-89.
14. Yusuf S, Garg R, Zucker D. Analysis by intention-to-treat principle in randomized trials and databases. PACE 1991;14:2078-82.
15. The SAS software. In: PHREG procedure, 1990:435-79.
16. Cox DR. Regression models and life tables. J Stat Soc (b) 1972;34:187-220.
17. Holt DW, Tucker GT, Jacson PR, Storey GCA. Amiodarone pharmacokinetics. Am Heart J 1983;106: 840.
18. Haffajee CI, Love JC, Canada AT, Lesko LJ, Askourian G, Alpert JS. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation 1983;67:1347-55.
19. Brugada P, Talajic M, Smeets J, Mullenders R, Wellens HJJ. Risk stratification of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction. The value of the clinical history. Eur Heart J 1989; 10:747-52.
20. Willems AR, Tijssen JGP, Van Capelle FJL, et al. Determinants of prognosis in symptomatic ventricular tachycardia or ventricular fibrillation late after myocardial infarction. J Am Coll Cardiol 1990;16:521-30.